featured
Safety and Immunogenicity of an rAd26 and rAd5 Vector–Based Heterologous Prime-Boost COVID-19 Vaccine in Two Formulations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Immunogenicity of an rAd26 and rAd5 Vector–Based Heterologous Prime-Boost COVID-19 Vaccine in Two Formulations: Two Open, Non-Randomised Phase 1/2 Studies From Russia
Lancet 2020 Sep 03;[EPub Ahead of Print], DY Logunov, IV Dolzhikova, OV Zubkova, AI Tukhvatullin, DV Shcheblyakov, AS Dzharullaeva, DM Grousova, AS Erokhova, AV Kovyrshina, AG Botikov, FM Izhaeva, O Popova, TA Ozharovskaya, IB Esmagambetov, IA Favorskaya, DI Zrelkin, DV Voronina, DN Shcherbinin, AS Semikhin, YV Simakova, EA Tokarskaya, NL Lubenets, DA Egorova, MM Shmarov, NA Nikitenko, LF Morozova, EA Smolyarchuk, EV Kryukov, VF Babira, SV Borisevich, BS Naroditsky, AL GintsburgFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.